Clark Capital Management Group Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Clark Capital Management Group Inc. bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 207,733 shares of the biopharmaceutical company's stock, valued at approximately $4,335,000. Clark Capital Management Group Inc. owned about 0.17% of Catalyst Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Barclays PLC raised its position in shares of Catalyst Pharmaceuticals by 129.4% in the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company's stock valued at $4,939,000 after buying an additional 140,129 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 3.4% during the third quarter. Franklin Resources Inc. now owns 59,164 shares of the biopharmaceutical company's stock valued at $1,221,000 after purchasing an additional 1,967 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Catalyst Pharmaceuticals by 9.1% during the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock valued at $8,116,000 after buying an additional 33,888 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter worth about $134,000. Finally, Richard P Slaughter Associates Inc lifted its holdings in Catalyst Pharmaceuticals by 1.9% during the fourth quarter. Richard P Slaughter Associates Inc now owns 149,406 shares of the biopharmaceutical company's stock valued at $3,118,000 after purchasing an additional 2,770 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Stephens reiterated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Robert W. Baird boosted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $32.29.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This represents a 25.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. The trade was a 39.47% decrease in their position. The disclosure for this sale can be found here. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX traded down $0.31 during trading hours on Wednesday, hitting $23.34. 426,579 shares of the stock were exchanged, compared to its average volume of 1,106,576. The stock's 50-day moving average price is $23.07 and its two-hundred day moving average price is $22.43. The company has a market cap of $2.85 billion, a price-to-earnings ratio of 19.78, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.75 and a 12-month high of $26.16.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.